148 related articles for article (PubMed ID: 24276187)
1. [Neuroendocrine differentiation in prostate adenocarcinoma].
Ramírez-Balderrama L; López-Briones S; Daza-Benítez L; Macías MH; López-Gaytán T; Pérez-Vázquez V
Gac Med Mex; 2013; 149(6):639-45. PubMed ID: 24276187
[TBL] [Abstract][Full Text] [Related]
2. Function and molecular mechanisms of neuroendocrine cells in prostate cancer.
Huang J; Wu C; di Sant'Agnese PA; Yao JL; Cheng L; Na Y
Anal Quant Cytol Histol; 2007 Jun; 29(3):128-38. PubMed ID: 17672372
[TBL] [Abstract][Full Text] [Related]
3. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
Bonkhoff H; Remberger K
Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation in prostate cancer.
Sun Y; Niu J; Huang J
Am J Transl Res; 2009 Feb; 1(2):148-62. PubMed ID: 19956427
[TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine cells in the prostatic carcinomas after neoadjuvant hormonal therapy.
Chen X; Okada H; Gotoh A; Arakawa S; Kamidono S
Kobe J Med Sci; 1997 Apr; 43(2):71-81. PubMed ID: 9385786
[TBL] [Abstract][Full Text] [Related]
8. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
Matsumoto Y; Mibu H; Kagebayashi Y
Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
[TBL] [Abstract][Full Text] [Related]
9. Human ASH-1 promotes neuroendocrine differentiation in androgen deprivation conditions and interferes with androgen responsiveness in prostate cancer cells.
Rapa I; Volante M; Migliore C; Farsetti A; Berruti A; Vittorio Scagliotti G; Giordano S; Papotti M
Prostate; 2013 Aug; 73(11):1241-9. PubMed ID: 23657976
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status.
Bonkhoff H
Prostate Suppl; 1998; 8():18-22. PubMed ID: 9690659
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine differentiation in human prostatic carcinoma.
di Sant'Agnese PA
Hum Pathol; 1992 Mar; 23(3):287-96. PubMed ID: 1313390
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer.
Huang J; Yao JL; Zhang L; Bourne PA; Quinn AM; di Sant'Agnese PA; Reeder JE
Am J Pathol; 2005 Jun; 166(6):1807-15. PubMed ID: 15920165
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.
Yuan TC; Veeramani S; Lin FF; Kondrikou D; Zelivianski S; Igawa T; Karan D; Batra SK; Lin MF
Endocr Relat Cancer; 2006 Mar; 13(1):151-67. PubMed ID: 16601285
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.
Yuan TC; Veeramani S; Lin MF
Endocr Relat Cancer; 2007 Sep; 14(3):531-47. PubMed ID: 17914087
[TBL] [Abstract][Full Text] [Related]
15. Correlation between histopathological form and the degree of neuroendocrine differentiations in prostate cancer.
Bocan EV; Mederle O; Sârb S; Minciu R; Agapie D; Raica M
Rom J Morphol Embryol; 2011; 52(4):1215-8. PubMed ID: 22203925
[TBL] [Abstract][Full Text] [Related]
16. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of neuroendocrine differentiation in prostate cancer.
Nelson EC; Cambio AJ; Yang JC; Ok JH; Lara PN; Evans CP
Prostate Cancer Prostatic Dis; 2007; 10(1):6-14. PubMed ID: 17075603
[TBL] [Abstract][Full Text] [Related]
18. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
[TBL] [Abstract][Full Text] [Related]
19. Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.
Valentini A; Biancolella M; Amati F; Gravina P; Miano R; Chillemi G; Farcomeni A; Bueno S; Vespasiani G; Desideri A; Federici G; Novelli G; Bernardini S
Drug Metab Dispos; 2007 Jun; 35(6):968-72. PubMed ID: 17371798
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
